Lung cancer is the leading cause of death for malignancy worldwide. Its molecular profiling
has enriched our understanding of cancer initiation and progression and has become …

The treatment of patients with advanced non-small-cell lung cancer (NSCLC) in recent years
has been increasingly guided by biomarker testing. Testing has centered on driver genetic …

Abstract Purpose: The European Organization for Research and Treatment of Cancer
(EORTC) clinical phase II trial 90101 “CREATE” showed high antitumor activity of crizotinib …

Background: Thousands of gene fusions have been reported in prostate cancer, but their
authenticity, incidence, and tumor specificity have not been thoroughly evaluated, nor have …

To address drug resistance caused by ALK kinase mutations, a series of novel 2, 4-
diarylaminopyrimidine (DAAP) analogues were designed by incorporating 1H-benzo [d] …

Aiming to develop ALK/ROS1 dual inhibitors overcoming ceritinib-resistant G1202R mutant,
a dedicated structure-guided modification campaign was conducted based on ALK co …

Targeted sequencing was performed from plasma-derived cell-free nucleic acid in twenty-
one advanced, treatment naïve, non-small-cell lung cancer (NSCLC) patients. Clinically …

The T-cell lymphomas are a rare group of Non-Hodgkin's lymphomas derived from mature T-
lymphocytes. They are divided broadly into the Peripheral T-cell lymphomas and the …

This book provides a comprehensive overview of the fast-evolving subject of clinical
application of cancer therapeutic biomarkers. The second edition captures significant …

Non-small cell lung cancer (NSCLC) accounts for 85% of all lung malignancies. Patients
with rare histological subtypes, including pulmonary large cell carcinoma (LCC), pulmonary …